SWX:NOVNPharmaceuticals
Novartis (SWX:NOVN) Wins EU Approval For Itvisma Across A Broad SMA Population
Novartis (SWX:NOVN) received European Commission approval for Itvisma, a one time gene replacement therapy for spinal muscular atrophy.
The authorization covers a broad SMA population in the EU, including children, teens, and adults.
Itvisma is described as the first and only single dose gene therapy in Europe that targets the genetic root cause of SMA across this age range.
Novartis has built a pharmaceuticals business around complex conditions, and the approval of Itvisma reinforces that...